Income statement, balance sheet and cash flow statement for the last 9 fiscal years, taken from the XBRL data Gossamer Bio, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2017
FY2019
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
0
0
115
48.5
Research and development
0.89
55.3
143
161
170
171
135
138
174
General and administrative
0.26
44.1
39.1
49.7
45.8
47.6
38.5
36.1
37.6
Operating expenses
6.65
149
186
234
216
219
184
175
219
Operating income
-6.65
-149
-186
-234
-216
-219
-184
-59.9
-171
Interest expense
0.01
1.94
12.7
19.4
13.9
13.5
11.5
11
Interest income
1.72
5.56
3.44
0.76
1.58
2
1.78
1.97
Other non-operating income
-0.12
2.02
5.83
-0.17
-17.9
-10.8
3.94
4.28
0.27
Pre-tax income
6.77
-147
-180
-243
-234
-229
-180
-55.6
-170
Income tax
0
0
0
0
0
0.89
-0.09
Net income
-6.77
-147
-180
-243
-234
-229
-180
-56.5
-170
EBITDA
-6.65
-149
-185
-233
-214
-217
-182
-59.1
-171
EPS, basic
-0.74
-22.59
-3.29
-3.55
-3.13
-2.71
-1.18
-0.25
-0.75
EPS, diluted
-0.74
-22.59
-3.29
-3.55
-3.13
-2.71
-1.18
-0.25
-0.75
Shares, basic (weighted)
9.16
6.5
54.7
68.5
74.8
84.6
153
226
229
Shares, diluted (weighted)
9.16
6.5
54.7
68.5
74.8
84.6
153
226
229
Balance sheet
FY2017
FY2019
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
0.32
105
135
486
183
112
32.1
46.1
37.7
Short-term investments
123
267
26.6
142
144
264
248
99.2
Receivables
0
5.34
12.2
Other current assets
3.1
7.49
9.13
6.5
6.2
10.1
10
18.5
Total current assets
232
409
522
332
262
307
310
168
Property, plant and equipment
3.19
5.43
5.53
5.32
3.98
1.65
0.01
0.06
Lease right-of-use assets
10.3
10.6
5.48
5.91
3.13
5.11
4.13
Long-term investments
0
Other non-current assets
4.27
1.56
1.03
1.08
0.68
0.62
0.28
0.41
Total assets
239
427
539
344
272
312
315
172
Accounts payable
2.18
0.96
7.51
3.24
1.46
5.53
2.32
5.96
Accrued liabilities
7.57
16.7
20.7
20.4
20.5
26.7
15.2
15.8
Deferred revenue
0
17.1
20
Short-term debt
0
11.6
11.6
0
Total current liabilities
20.4
36.9
38.7
39.9
49.2
51.6
45
63.4
Long-term debt
28.5
28.7
29.1
12
0.81
0
Lease liabilities
8.74
7.71
3.22
3.45
0.14
4.4
3.46
Total liabilities
21.1
74.1
219
222
260
249
286
295
Total debt
28.5
28.7
29.1
23.6
12.4
0
Paid-in capital
33.9
686
898
933
1,045
1,275
1,297
1,321
Retained earnings
-154
-334
-578
-812
-1,032
-1,212
-1,269
-1,439
Other comprehensive income
-0.06
0.26
0.6
0.05
-0.57
-0.35
1.19
-5.15
Shareholders' equity
-6.86
-120
352
321
121
12.1
62.8
29.5
-123
Total equity
-6.86
-120
352
321
121
12.1
62.8
29.5
-123
Total liabilities and equity
239
427
539
344
272
312
315
172
Shares outstanding
8.05
61.6
73.9
75.8
94.4
225
227
234
Cash flow statement
FY2017
FY2019
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-6.77
-147
-180
-243
-234
-229
-180
-56.5
-170
Depreciation and amortization
0
0.3
0.92
1.41
1.74
1.83
1.61
0.83
0.02
Stock-based compensation
0.03
30.9
20.8
38.7
32
42.6
28.5
20.6
10.6
Deferred income tax
0
0
0
Change in receivables
0
0
-5.34
-6.89
Change in payables
0.06
2.09
-1.4
6.98
-4.43
-1.81
3.99
-1.66
-2.75
Cash from operations
-5.75
-51
-145
-176
-189
-187
-159
-3.47
-171
Capital expenditures
-3.49
-2.97
-1.5
-1.55
-0.41
0
0
-0.08
Purchases of investments
-124
-499
-109
-152
-238
-442
-495
-227
Cash from investing
-145
-147
215
-117
-1.04
-111
29
156
Debt issued
28.2
Debt repaid
0
0
-5.81
-11.6
-12.6
0
Stock issued
0
291
117
0
0
0
0
1.93
Cash from financing
6
301
322
313
3.33
117
190
-11.5
6.43
Net change in cash
0.26
105
29.7
352
-303
-71.5
-79.9
14
-8.34
Free cash flow
-54.5
-148
-178
-190
-187
-159
-3.47
-171
Interest paid
0.12
1.48
7.87
12.7
12.7
12.3
10.6
10
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $10.94 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-311.7%
Operating income / revenue.
Net margin
-235.0%
Net income / revenue.
FCF margin
-305.2%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-305.2%
Cash from operations / revenue.
Return on assets (ROA)
-162.9%
Net income / average total assets.
R&D / revenue
307.7%
Research and development expense / revenue.
Stock-based pay / revenue
26.9%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
0.0%
Capital expenditures / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-57.7%
Revenue vs the same period a year earlier. Only from a positive base.
Book value growth, 1y
-516.2%
Book value vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
-45.4%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-14.2%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-20.4%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
1.0%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
39.3%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
27.2%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
0.53x
Current assets / current liabilities.
Quick ratio
0.46x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.41x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.16
Revenue / diluted weighted shares.
FCF per share
-$0.49
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$0.49
Cash from operations / diluted weighted shares.
Book value per share
-$0.19
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
100x
Market cap / revenue.
EV/Sales
99.3x
Enterprise value / revenue.
FCF yield
-3.0%
Free cash flow / market cap.
Earnings yield
-2.3%
Net income / market cap (the inverse of P/E).
What was Gossamer Bio, Inc.'s revenue in fiscal 2025?
Gossamer Bio, Inc. reported revenue of $48.5M for fiscal 2025, 57.7% lower than the year before.
Was Gossamer Bio, Inc. profitable in fiscal 2025?
No. It reported a net loss of $170.4M.
How much free cash flow did Gossamer Bio, Inc. generate in fiscal 2025?
Cash from operations of $171.3M minus capital expenditures of $79.0K left free cash flow of -$171.3M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.